Back to Headlines
Health
May 18, 2026
Analyzed by GPT OSS 120B

Campaigners Threaten Legal Action Over UK-US Drug Pricing Deal

AI Summary
Campaign groups are warning the UK government that they will seek a judicial review unless a new statutory instrument allowing ministers to overrule NICE on drug pricing is revoked. The move is tied to a controversial UK‑US agreement on pharmaceutical tariffs and has sparked concerns over transparency and NHS cost controls.

Legal Threats Emerge Over UK‑US Drug Pricing Agreement

Campaigners Global Justice Now and Just Treatment have issued a nine‑page “letter before claim” stating they will pursue a judicial review if the Department of Health and Social Care (DHSC) does not repeal a statutory instrument that lets the health secretary overrule the independent judgment of NICE on NHS drug prices.

Statutory Instrument Gives Ministers Power to Override NICE

  • The secondary legislation came into force last month, granting ministers authority to direct how much the NHS should pay for certain medicines.
  • Both groups argue this constitutes an “unlawful power grab” that breaches the Health and Social Care Act 2012.
  • Former health secretary Andrew Lansley has also labelled the instrument unlawful.

Opaque Cost Data Undermines Parliamentary Scrutiny

  • MPs from multiple parties have criticised the government’s refusal to publish an impact assessment of the decade‑long UK‑US deal.
  • No concrete figures on the long‑term cost to the NHS have been released, limiting debate in the Commons.

Potential Erosion of NICE Independence Risks NHS Price Controls

  • NICE is globally respected for its independent cost‑effectiveness assessments.
  • Overriding its recommendations could lead to higher drug prices for the NHS, undermining the mechanism that keeps “big pharma’s overinflated prices” in check.
  • Campaigners warn the move jeopardises patient safety and democratic oversight.

Future Legal Battles May Shape UK Drug Policy Landscape

  • If the judicial review proceeds, courts will examine whether the statutory instrument conflicts with existing health legislation.
  • Continued parliamentary pressure may force the government to renegotiate aspects of the UK‑US tariff‑free drug export agreement.
  • The outcome could set a precedent for how future health‑related secondary legislation is crafted and scrutinised.